MedPath

Effects of Remimazolam on Intraoperative Blood Pressure Control in Interventional Cerebral Aneurysm Coil Embolizatio

Not Applicable
Conditions
Diseases of the circulatory system
Registration Number
KCT0008343
Lead Sponsor
Korea University Anam Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Patients over age 19 undergoing elective cerebral aneurysm coil embolization at Korea University hospital under general anesthesia, who have agreed to terms.

Exclusion Criteria

Patients who have already been intubated and sedated before general anesthesia
Patients without tracheal extubation after coil embolization
Patients with hemodynamic instability, such as shock or coma
Patients with hypersensitivity or specific reactions to narcotic drugs, including sevoflurane and remifentanil, and benzodiazepines
Patients who are an absolute contraindication to the administration of remimazolam; Patients with acute narrow-angle glaucoma, patients with acute alcoholism with suppressed vital signs, patients with severe or acute respiratory failure, patients with genetic lactose intolerance such as galactose intolerance, patients with severe hypersensitivity to dextran 40
Patients with mental retardation or difficulties in reading Korean
Subjects who are vulnerable to research (research participants who are vulnerable to coercion or undue influence, or those who lack decision-making ability; pregnant women, fetuses/newborns, minors, those who lack decision-making ability, students, staff, voluntary decision to participate due to surrounding environment susceptible to)
Patients unable to continuously monitor arterial blood pressure through the radial artery

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Intraoperative blood pressure
Secondary Outcome Measures
NameTimeMethod
Intraoperative heart rate, vasopressor usage, mortality within 30 days POD, delirium 7days POD, AKI 7 days POD (according to KDIGO guideline)
© Copyright 2025. All Rights Reserved by MedPath